Subject matters | Details | Categories |
---|---|---|
Health
|
Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB).
|
Regulation
|
Health
|
Encouraging the development of a rare disease strategy in Canada (similar to the policies for rare diseases in Europe and the United States).
|
Policies or Program
|
Health
|
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
|
Policies or Program
|
Research and Development
|
Increased federal investment in health-related research. We worked with the Health Charities Coalition of Canada (HCCC) to draft content for a press release urging the federal government to invest more in basic science in Canada.
|
Policies or Program, Grant, Contribution or Other Financial Benefit
|
Research and Development
|
In terms of research and development, we lobby for support of cystic fibrosis research initiatives that improve the health and wellness of Canadians living with cystic fibrosis.
|
Grant, Contribution or Other Financial Benefit, Policies or Program
|
Science and Technology
|
In terms of science and technology, we work toward the development of precision and personalized medicines that target the basic defect of cystic fibrosis. We are exploring how the federal government may support these efforts through partnership and funding.
|
Policies or Program, Grant, Contribution or Other Financial Benefit
|
Labour
|
With respect to disability, we advocate for recognition of and supports for people with episodic disabilities.
|
Policies or Program
|
Cystic Fibrosis Canada is a health charity that supports cystic fibrosis (CF)-related research and care with the goal of finding a cure or effective control for CF, and educates the public about the disease.
Kelly Grover, President and Chief Executive Officer
End date of the last completed financial year: 2023-12-31
Government Institution | Funding Received in Last Financial Year | Funding Expected in Current Financial Year |
---|---|---|
BC Ministry of Health | $0.00 | Yes |
Employment and Social Development Canada (ESDC) | $21,350.00 | Yes |
Address:
20 Eglinton Avenue West
Suite 1305
Toronto, ON M4R 1K8
Canada
Telephone number:
416-485-9149
Ext.
238
This is the responsible officer name as provided in the most recent registration for the corporation or organization.
Name | From | To |
---|---|---|
Cystic Fibrosis Canada/Fibrose kystique Canada | 2024-06-06 | current |
Cystic Fibrosis Canada/Fibrose kystique Canada | 2011-03-23 | 2024-06-06 |
Canadian Cystic Fibrosis Foundation/Fondation canadienne de la fibrose kystique | 2010-09-01 | 2011-03-23 |
Responsible Officer Name | From (YYYY-MM-DD) | To (YYYY-MM-DD) |
---|---|---|
Kelly Grover | 2018-06-04 | Current |
Norma Beauchamp | 2016-04-19 | 2017-11-03 |
Maureen Adamson | 2011-02-01 | 2014-12-02 |
Cathleen Morrison | 2010-09-01 | 2011-02-01 |
Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.
Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.
Results below are sorted by posted date, beginning with the most recent.
Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.
Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.
Results below are sorted by posted date, beginning with the most recent.